BioSpace News Archive

Prometheus Biosciences, Inc. announced that it intends to offer and sell, subject to market and other conditions, $250 million of shares of its common stock in an underwritten public offering.

Revolution Medicines, Inc., a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, announced that Sanofi has provided notice of termination of the parties’ global SHP2 development and commercialization collaboration.

Congruence Therapeutics, a biotechnology company working at the interface of computational and experimental drug discovery to design novel small molecules for diseases of protein misfolding, announced today that Congruence’s CEO, Dr. Clarissa Desjardins, will present a corporate overview at the Biotech Showcase 2023 meeting on Monday, January 9, 2023, at 3:30 PM.

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or the “Company”) announced that it has received the U.S. Food and Drug Administration’s (FDA) clinical hold letter in regards to the Company’s IkT-148009 programs in Parkinson’s disease and Multiple System Atrophy.

Kezar Life Sciences, Inc. announced that the Compensation Committee of the company’s Board of Directors granted four employees nonqualified stock options to purchase 65,500 shares of its common stock with an exercise price of $7.07 per share, which is equal to the closing price of Kezar’s common stock on December 5, 2022, the grant date of the awards.

IMV Inc. announced that at the special meeting of shareholders held on December 7, 2022, the share consolidation as described in the management information circular filed on October 28, 2022 was approved by the shareholders at 87.87% of the shares voted and that its board of directors has approved a 1-for-10 reverse stock split of IMV’s common shares immediately thereafter.

Neuronetics, Inc., a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced the granting of inducement awards to Rusty Page, VP Operations.

Touchlight announces a development and supply agreement with Odimma Therapeutics, a French biotech company focusing on personalised cancer immunotherapy.

Metrion Biosciences Limited and The KCNC1 Foundation announced a collaboration to progress a hit identification research project for small molecule modulators of the potassium ion channel Kv3.1, targeting KCNC1-related disorders.

A new treatment is significantly more effective in improving symptoms of moderate to severe hip osteoarthritis in dogs than glucocorticoid alone, according a study published this week in “Advances in Diagnostic and Treatment Methods for Joint Diseases in Dogs and Cats,” a special issue published by the veterinary journal Animals.